Organosilicon molecules with medicinal applications

Journal of Medicinal Chemistry

Volumn 56, Issue 2, 2013, Pages 388-405

  Franz, Annaliese K ^a   Wilson, Sean O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; BORTEZOMIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MK 056; ORGANOSILICON DERIVATIVE; PYRAZOLE DERIVATIVE; SILACYCLOPENTANE; SILANEDIOL DERIVATIVE; SILANETRIOL DERIVATIVE; SILANOL; SILAVENLAFAXINE; TAGRETIN; TRIMETHYLSILYLPYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST; VENLAFAXINE;

ANTIMICROBIAL ACTIVITY; BIOLOGICAL ACTIVITY; CARDIOSELECTIVITY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HYDROGEN BOND; HYDROSILYLATION; LIPOPHILICITY; PROTEIN BINDING; REVIEW; STEREOCHEMISTRY; SUBSTITUTION REACTION;

EID: 84872790950     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3010114     Document Type: Review

References (113)

1. Tacke, R.; Heinrich, T.; Bertermann, R.; Burschka, C.; Hamacher, A.; Kassack, M. U. Sila-haloperidol: a silicon analogue of the dopamine (D2) receptor antagonist haloperidol Organometallics 2004, 23, 4468-4477
2. Wannagat, U.; Wiese, D.; Struckmeier, G.; Thewalt, U.; Debaerdemaeker, T. Sila-pharmaceuticals. 38. Structure and pharmacological effectiveness of sila-substituted analogs of the psychopharmacological agent dimetacrine Liebigs Ann. Chem. 1988, 241-248
3. Barnes, M. J.; Conroy, R.; Miller, D. J.; Mills, J. S.; Montana, J. G.; Pooni, P. K.; Showell, G. A.; Walsh, L. M.; Warneck, J. B. H. Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: a new use of silicon bioisosteres in medicinal chemistry Bioorg. Med. Chem. Lett. 2007, 17, 354-357
4. Lukevics, E.; Germane, S.; Segal, I.; Zablotskaya, A. Silyl modification of biologically active compounds. 4. Derivatives of amino acids in the tetrahydroquinoline, tetrahydroisoquinoline, and tetrahydrosilaisoquinoline series Chem. Heterocycl. Compd. (N. Y., NY, U. S.) 1997, 33, 234-238
5. Sieburth, S. McN.; Nittoli, T.; Mutahi, A. M.; Guo, L. Silanediols: A new class of potent protease inhibitors Angew. Chem., Int. Ed. 1998, 37, 812-814
6. Tacke, R.; Handmann, V. I.; Bertermann, R.; Burschka, C.; Penka, M.; Seyfried, C. Sila-analogues of high-affinity, selective σ ligands of the spiro[indane-1,4′-piperidine] type: syntheses, structures, and pharmacological properties Organometallics 2003, 22, 916-924
7. Richardson, P. G.; Hideshima, T.; Anderson, K. C. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers Cancer Control 2003, 10, 361-369
8. Bains, W.; Tacke, R. Silicon chemistry as a novel source of chemical diversity in drug design Curr. Opin. Drug Discovery Dev. 2003, 6, 526-543
9. Gately, S.; West, R. Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds Drug Dev. Res. 2007, 68, 156-163
10. Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design J. Med. Chem. 2011, 54, 2529-2591
11. Brook, M. A. Silicon in Organic, Organometallic, and Polymer Chemistry; John Wiley & Sons: New York, 2000.
12. 2OH J. Organomet. Chem. 1977, 129, C28-C32
13. Tacke, R.; Linoh, H. Bioorganosilicon Chemistry. In Organic Silicon Compounds; John Wiley & Sons, Ltd.: New York, 1989; Vol. 2, pp 1143-1206.
14. Showell, G. A.; Mills, J. S. Chemistry challenges in lead optimization: silicon isosteres in drug discovery Drug Discovery Today 2003, 8, 551-556
15. Mills, J. S.; Showell, G. A. Exploitation of silicon medicinal chemistry in drug discovery Expert Opin. Invest. Drugs 2004, 13, 1149-1157
16. Pooni, P. K.; Showell, G. A. Silicon switches of marketed drugs Mini-Rev. Med. Chem. 2006, 6, 1169-1177
17. Sieburth, S. Mc N.; Chen, C.-A. Silanediol protease inhibitors: from conception to validation Eur. J. Org. Chem. 2006, 311-322
18. Franz, A. K. The synthesis of biologically active organosilicon small molecules Curr. Opin. Drug Discovery Dev. 2007, 10, 654-671
19. Weidmann, B. (trimethylsilyl)alanine: a metabolically stable "bio-isostere" for phenylalanine Chimia 1992, 46, 312-313
20. Pujals, S.; Fernandez-Carneado, J.; Kogan, M. J.; Martinez, J.; Cavelier, F.; Giralt, E. Replacement of a proline with silaproline causes a 20-fold increase in the cellular uptake of a Pro-rich peptide J. Am. Chem. Soc. 2006, 128, 8479-8483
21. Vivet, B.; Cavelier, F.; Martinez, J. Synthesis of silaproline, a new proline surrogate Eur. J. Org. Chem. 2000, 807-811
22. Mortensen, M.; Husmann, R.; Veri, E.; Bolm, C. Synthesis and applications of silicon-containing α-amino acids Chem. Soc. Rev. 2009, 38, 1002-1010
23. Tacke, R.; Merget, M.; Bertermann, R.; Bernd, M.; Beckers, T.; Reissmann, T. Syntheses and properties of silicon-and germanium-containing α-amino acids and peptides: a study on C/Si/Ge bioisosterism Organometallics 2000, 19, 3486-3497
24. Tsuji, Y.; Yamanaka, H.; Fukui, T.; Kawamoto, T.; Tanaka, A. Enzymic preparation of D-4-(trimethylsilyl)phenylalanine Appl. Microbiol. Biotechnol. 1997, 47, 114-119
25. Cavelier, F.; Vivet, B.; Martinez, J.; Aubry, A.; Didierjean, C.; Vicherat, A.; Marraud, M. Influence of silaproline on peptide conformation and bioactivity J. Am. Chem. Soc. 2002, 124, 2917-2923
26. Cavelier, F.; Marchand, D.; Martinez, J.; Sagan, S. Biological activity of silylated amino acid containing substance p analogues J. Pept. Res. 2004, 63, 290-296
27. Liu, G.; Sieburth, S. McN. Enantioselective α-silyl amino acid synthesis by reverse-aza-Brook rearrangement Org. Lett. 2003, 5, 4677-4679
28. 3)COOH into biologically active decapeptides: a study on C/Si/Ge bioisosterism J. Organomet. Chem. 2001, 628, 183-194
29. Kotha, S.; Brahmachary, E. Synthesis and reactions of silicon-containing cyclic alpha-amino acid derivatives J. Organomet. Chem. 2004, 689, 158-163
30. Zakai, U. I.; Bikzhanova, G.; Staveness, D.; Gately, S.; West, R. Synthesis of lipophilic sila derivatives of N -acetylcysteineamide, a cell permeating thiol Appl. Organomet. Chem. 2010, 24, 189-192
31. Bikzhanova, G. A.; Toulokhonova, I. S.; Gately, S.; West, R. Novel silicon-containing drugs derived from the indomethacin scaffold: synthesis, characterization and evaluation of biological activity Silicon Chem. 2007, 3, 209-217
32. Hernandez, D.; Mose, R.; Skrydstrup, T. Reductive lithiation of methyl substituted diarylmethylsilanes: application to silanediol peptide precursors Org. Lett. 2011, 13, 732-735
33. Sen, S.; Purushotham, M.; Qi, Y.; Sieburth, S. McN. Efficient asymmetric synthesis of silanediol precursors from 1,5-dihydrosiloles Org. Lett. 2007, 9, 4963-4965
34. Nielsen, L.; Skrydstrup, T. Sequential C-Si bond formations from diphenylsilane: application to silanediol peptide isostere precursors J. Am. Chem. Soc. 2008, 130, 13145-13151
35. Hernandez, D.; Lindsay, K. B.; Nielsen, L.; Mittag, T.; Bjerglund, K.; Friis, S.; Mose, R.; Skrydstrup, T. Further studies toward the stereocontrolled synthesis of silicon-containing peptide mimics J. Org. Chem. 2010, 75, 3283-3293
36. Nielsen, L.; Lindsay, K. B.; Faber, J.; Nielsen, N. C.; Skrydstrup, T. Stereocontrolled synthesis of methyl silanediol peptide mimics J. Org. Chem. 2007, 72, 10035-10044
37. Bo, Y.; Singh, S.; Duong, H. Q.; Cao, C.; Sieburth, S. McN. Efficient, enantioselective assembly of silanediol protease inhibitors Org. Lett. 2011, 13, 1787-1789
38. Johansson, T.; Weidolf, L.; Popp, F.; Tacke, R.; Jurva, U. In vitro metabolism of haloperidol and sila-haloperidol: new metabolic pathways resulting from carbon/silicon exchange Drug Metab. Dispos. 2010, 38, 73-83
39. Osterholtz, F. D.; Pohl, E. R. Kinetics of the hydrolysis and condensation of organofunctional alkoxysilanes: A review J. Adhes. Sci. Technol. 1992, 6, 127-149
40. Liu, G.; Sieburth, S. McN. α-Trialkylsilyl amino acid stability Org. Lett. 2005, 7, 665-668
41. Chiu, F. T.; Chang, Y. H.; Ozkan, G.; Zon, G.; Fichter, K. C.; Phillips, L. R. Synthesis, hydrolytic reactivity, and anticancer evaluation of N-and O -triorganosilylated compounds as new types of potential prodrugs J. Pharm. Sci. 1982, 71, 542-551
42. Millership, J. S.; Shanks, M. L. Prodrugs utilizing organosilyl derivation: an investigation of the long-term androgenic and myotropic activities of silyl derivatives of testosterone J. Pharm. Sci. 1988, 77, 116-119
43. Tremont, S. J.; Collins, P. W.; Perkins, W. E.; Fenton, R. L.; Forster, D.; McGrath, M. P.; Wagner, G. M.; Gasiecki, A. F.; Bianchi, R. G. Catalytic functionalization of polymers: a novel approach to site-specific delivery of misoprostol to the stomach J. Med. Chem. 1993, 36, 3087-3097
44. Parrott, M. C.; Finniss, M.; Luft, J. C.; Pandya, A.; Gullapalli, A.; Napier, M. E.; DeSimone, J. M. Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles J. Am. Chem. Soc. 2012, 134, 7978-7982
45. Dong, F.; Guo, W.; Chu, S.-W.; Ha, C.-S. Novel fluorinated polysilsesquioxane hollow spheres: synthesis and application in drug release Chem. Commun. (Cambridge, U. K.) 2010, 46, 7498-7500
46. Otsuka, M.; Tokumitsu, K.; Matsuda, Y. Solid dosage form preparations from oily medicines and their drug release. Effect of degree of surface-modification of silica gel on the drug release from phytonadione-loaded silica gels J. Controlled Release 2000, 67, 369-384
47. Wei, Q.; Wang, F.; Nie, Z.-R.; Song, C.-L.; Wang, Y.-L.; Li, Q.-Y. Highly hydrothermally stable microporous silica membranes for hydrogen separation J. Phys. Chem. B 2008, 112, 9354-9359
48. Donadel, O. J.; Martin, T.; Martin, V. S.; Villar, J.; Padron, J. M. The tert -butyl dimethyl silyl group as an enhancer of drug cytotoxicity against human tumor cells Bioorg. Med. Chem. Lett. 2005, 15, 3536-3539
49. Carrillo, R.; Leon, L. G.; Martin, T.; Martin, V. S.; Padron, J. M. Synthesis and antiproliferative activity of (2 R,3 R)-disubstituted tetrahydropyrans Bioorg. Med. Chem. Lett. 2006, 16, 6135-6138
50. Szilagyi, A.; Fenyvesi, F.; Majercsik, O.; Pelyvas, I. F.; Bacskay, I.; Feher, P.; Varadi, J.; Vecsernyes, M.; Herczegh, P. Synthesis and cytotoxicity of leinamycin antibiotic analogues J. Med. Chem. 2006, 49, 5626-5630
51. Gately, S.; West, R. Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds Drug Dev. Res. 2007, 68, 156-163
52. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate J. Med. Chem. 2002, 45, 2994-3008
53. Daiss, J. O.; Burschka, C.; Mills, J. S.; Montana, J. G.; Showell, G. A.; Fleming, I.; Gaudon, C.; Ivanova, D.; Gronemeyer, H.; Tacke, R. Synthesis, crystal structure analysis, and pharmacological characterization of disila-bexarotene, a disila-analogue of the RXR-selective retinoid agonist bexarotene Organometallics 2005, 24, 3192-3199
54. Montana, J. G.; Fleming, I.; Tacke, R.; Daiss, J. Preparation of Heterocyclic Silicon Compounds and Their Use in the Treatment of Diseases or Conditions Associated with GnRH (Gonadotropin-Releasing Hormone). 2003-GB5015 2004045625, 20031119, 2004.
55. Bauer, J. B.; Lippert, W. P.; Doerrich, S.; Tebbe, D.; Burschka, C.; Christie, V. B.; Tams, D. M.; Henderson, A. P.; Murray, B. A.; Marder, T. B.; Przyborski, S. A.; Tacke, R. Novel silicon-containing analogues of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells ChemMedChem 2011, 6, 1509-1517
56. Tacke, R.; Müller, V.; Büttner, M. W.; Lippert, W. P.; Bertermann, R.; Daiß, J. O.; Khanwalkar, H.; Furst, A.; Gaudon, C.; Gronemeyer, H. Synthesis and pharmacological characterization of disila-AM80 (disila-tamibarotene) and disila-AM580, silicon analogues of the RARα-selective retinoid agonists AM80 (tamibarotene) and AM580 ChemMedChem 2009, 4, 1797-1802
57. Rew, Y.; McMinn, D. L.; Wang, Z.; He, X.; Hungate, R. W.; Jaen, J. C.; Sudom, A.; Sun, D.; Tu, H.; Ursu, S.; Villemure, E.; Walker, N. P. C.; Yan, X.; Ye, Q.; Powers, J. P. Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 1797-1801
58. Chang, M.; Park, S.-R.; Kim, J.; Jang, M.; Park, J. H.; Park, J. E.; Park, H.-G.; Suh, Y.-G.; Jeong, Y. S.; Park, Y.-H.; Kim, H.-D. Silicon switch approach in TRPV1 antagonist MK-056 and its analogues Bioorg. Med. Chem. 2010, 18, 111-116
59. Wang, J.; Ma, C.; Wu, Y.; Lamb, R. A.; Pinto, L. H.; DeGrado, W. F. Exploring organosilane amines as potent inhibitors and structural probes of influenza A virus M2 proton channel J. Am. Chem. Soc. 2011, 133, 13844-13847
60. Daiss, J. O.; Burschka, C.; Mills, J. S.; Montana, J. G.; Showell, G. A.; Warneck, J. B. H.; Tacke, R. Sila-venlafaxine, a sila-analogue of the serotonin/noradrenaline reuptake inhibitor venlafaxine: synthesis, crystal structure analysis, and pharmacological characterization Organometallics 2006, 25, 1188-1198
61. Daiss, J. O.; Penka, M.; Burschka, C.; Tacke, R. The Si-2,4,6- trimethoxyphenyl moiety as a novel protecting group in organosilicon chemistry: alternative synthesis of rac-sila-venlafaxine Organometallics 2004, 23, 4987-4994
62. Daiss, J. O.; Burschka, C.; Mills, J. S.; Montana, J. G.; Showell, G. A.; Warneck, J. B. H.; Tacke, R. Synthesis, crystal structure analysis, and pharmacological characterization of desmethoxy-sila-venlafaxine, a derivative of the serotonin/noradrenaline reuptake inhibitor sila-venlafaxine J. Organomet. Chem. 2006, 691, 3589-3595
63. Showell, G. A.; Barnes, M. J.; Daiss, J. O.; Mills, J. S.; Montana, J. G.; Tacke, R.; Warneck, J. B. H. (R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis Bioorg. Med. Chem. Lett. 2006, 16, 2555-2558
64. Tacke, R.; Popp, F.; Mueller, B.; Theis, B.; Burschka, C.; Hamacher, A.; Kassack, M. U.; Schepmann, D.; Wuensch, B.; Jurva, U.; Wellner, E. Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate ChemMedChem 2008, 3, 152-164
65. Tacke, R.; Nguyen, B.; Burschka, C.; Lippert, W. P.; Hamacher, A.; Urban, C.; Kassack, M. U. Sila-trifluperidol, a silicon analogue of the dopamine (D2) receptor antagonist trifluperidol: synthesis and pharmacological characterization Organometallics 2010, 29, 1652-1660
66. Sieburth, S. McN.; Chen, C.-A. Silanediol protease inhibitors: from conception to validation Eur. J. Org. Chem. 2006, 311-322
67. Singh, S.; Sieburth, S. McN. Serine protease inhibition by a silanediol peptidomimetic Org. Lett. 2012, 14, 4422-4425
68. Juers, D. H.; Kim, J.; Matthews, B. W.; Sieburth, S. McN. Structural analysis of silanediols as transition-state-analogue inhibitors of the benchmark metalloprotease thermolysin Biochemistry 2005, 44, 16524-16528
69. Organ, M. G.; Buon, C.; Decicco, C. P.; Combs, A. P. A concise synthesis of silanediol-based transition-state isostere inhibitors of proteases Org. Lett. 2002, 4, 2683-2685
70. Hernandez, D.; Nielsen, L.; Lindsay, K. B.; Lopez-Garcia, M. A.; Bjerglund, K.; Skrydstrup, T. Stereocontrolled synthesis of 2-substituted-1,3- azasilaheterocycles Org. Lett. 2010, 12, 3528-3531
71. Ballweg, D. M.; Miller, R. C.; Gray, D. L.; Scheidt, K. A. Stereoselective synthesis of α-silylamines by the direct addition of silyl anions to activated imines Org. Lett. 2005, 7, 1403-1406
72. Madsen, J. L. H.; Andersen, T. L.; Santamaria, S.; Nagase, H.; Enghild, J. J.; Skrydstrup, T. Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase J. Med. Chem. 2012, 55, 7900-7908
73. Min, G. K.; Skrydstrup, T. Regioselective Rh(I)-catalyzed sequential hydrosilylation toward the assembly of silicon-based peptidomimetic analogues J. Org. Chem. 2012, 77, 5894-5906
74. Kim, J. K.; Sieburth, S. McN. Synthesis and properties of a sterically unencumbered δ-silanediol amino acid J. Org. Chem. 2012, 77, 2901-2906
75. Anderson, T. F.; Statham, M. A. J.; Carroll, M. A. Bis(2-thienyl)silanes: new, versatile precursors to arylsilanediols Tetrahedron Lett. 2006, 47, 3353-3355
76. Blunder, M.; Hurkes, N.; Spirk, S.; List, M.; Pietschnig, R. Silanetriols as in vitro inhibitors for AChE Bioorg. Med. Chem. Lett. 2011, 21, 363-365
77. Kim, Y.-m.; Farrah, S.; Baney, R. H. Structure-antimicrobial activity relationship for silanols, a new class of disinfectants, compared with alcohols and phenols Int. J. Antimicrob. Agents 2007, 29, 217-222
78. Kim, Y.-m.; Farrah, S.; Baney, R. H. Silanol-a novel class of antimicrobial agent Electron. J. Biotechnol. 2006, 9, 176-180
79. Tran, N. T.; Min, T.; Franz, A. K. Silanediol hydrogen bonding activation of carbonyl compounds Chem.-Eur. J. 2011, 17, 9897-9900
80. Liu, M.; Tran, N. T.; Franz, A. K.; Lee, J. K. Gas-phase acidity studies of dual hydrogen-bonding organic silanols and organocatalysts J. Org. Chem. 2011, 76, 7186-7194
81. Tran, N. T.; Wilson, S. O.; Franz, A. K. Cooperative hydrogen-bonding effects in silanediol catalysis Org. Lett. 2012, 14, 186-189
82. Schafer, A. G.; Wieting, J. M.; Mattson, A. E. Silanediols: a new class of hydrogen bond donor catalysts Org. Lett. 2011, 13, 5228-5231
83. Beemelmanns, C.; Husmann, R.; Whelligan, D. K.; Özç ubukçu, S.; Bolm, C. Planar-chiral bis-silanols and diols as H-bonding asymmetric organocatalysts Eur. J. Org. Chem. 2012, 2012, 3373-3376
84. Min, T.; Fettinger, J. C.; Franz, A. K. Enantiocontrol with a hydrogen-bond directing pyrrolidinylsilanol catalyst ACS Catal. 2012, 2, 1661-1666
85. Daud, A.; Valkov, N.; Centeno, B.; Derderian, J.; Sullivan, P.; Munster, P.; Urbas, P.; DeConti, R. C.; Berghorn, E.; Liu, Z.; Hausheer, F.; Sullivan, D. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study Clin. Cancer Res. 2005, 11, 3009-3016
86. Bom, D.; Curran, D. P.; Kruszewski, S.; Zimmer, S. G.; Strode, J. T.; Kohlhagen, G.; Du, W.; Chavan, A. J.; Fraley, K. A.; Bingcang, A. L.; Latus, L. J.; Pommier, Y.; Burke, T. G. The novel silatecan 7-tert -butyldimethylsilyl-10- hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity J. Med. Chem. 2000, 43, 3970-3980
87. Venditto, V. J.; Simanek, E. E. Cancer therapies utilizing the camptothecins: a review of the in vivo literature Mol. Pharmaceutics 2010, 7, 307-349
88. Gabizon, A. A.; Tzemach, D.; Horowitz, A. T.; Shmeeda, H.; Yeh, J.; Zalipsky, S. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes Clin. Cancer Res. 2006, 12, 1913-1920
89. Gabarda, A. E.; Curran, D. P. Solution-phase parallel synthesis of 115 homosilatecan analogues J. Comb. Chem. 2003, 5, 617-624
90. Curran, D. P.; Du, W. Palladium-promoted cascade reactions of isonitriles and 6-iodo-N -propargylpyridones: synthesis of mappicines, camptothecins, and homocamptothecins Org. Lett. 2002, 4, 3215-3218
91. Moser, M.; Banfield, S. C.; Rinner, U.; Chapuis, J.-C.; Pettit, G. R.; Hudlicky, T. Cyclotrimerization approach to unnatural structural modifications of pancratistatin and other amaryllidaceae constituents-synthesis and biological evaluation Can. J. Chem. 2006, 84, 1313-1337
92. Miranda, P. O.; Padron, J. M.; Padron, J. I.; Villar, J.; Martin, V. S. Prins-type synthesis and SAR study of cytotoxic alkyl chloro dihydropyrans ChemMedChem 2006, 1, 323-329
93. Leon, L. G.; Miranda, P. O.; Martin, V. S.; Padron, J. I.; Padron, J. M. Antiproliferative activity of 4-chloro-5,6-dihydro-2 H -pyrans. Part 2: Enhancement of drug cytotoxicity Bioorg. Med. Chem. Lett. 2007, 17, 3087-3090
94. Aldeco-Perez, E.; Rudler, H.; Parlier, A.; Alvarez, C.; Apan, M. T.; Herson, P.; Toscano, A. A simple synthesis of cytotoxic endoperoxide lactones Tetrahedron Lett. 2006, 47, 9053-9056
95. Ramirez, A.; Woerpel, K. A. Synthesis of 1,2-dioxolanes by annulation reactions of peroxycarbenium ions with alkenes Org. Lett. 2005, 7, 4617-4620
96. Franz, A. K.; Dreyfuss, P. D.; Schreiber, S. L. Synthesis and cellular profiling of diverse organosilicon small molecules J. Am. Chem. Soc. 2007, 129, 1020-1021
97. 18F]fluoroboron-based biomolecules for PET imaging Curr. Radiopharm. 2010, 3, 224-242
98. 18F-labeling J. Am. Chem. Soc. 2005, 127, 13094-13095
99. 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor Angew. Chem., Int. Ed. 2006, 45, 6047-6050
100. 18F]fluoroethoxybis(1-methylethyl)silyl] propanamine-based prosthetic groups J. Fluorine Chem. 2011, 132, 250-257
101. 18F-radiolabelling Nucl. Med. Biol. 2009, 36, 895-905
102. 18F-labeled silicon-based PET tracers and their hydrolytic stability: experimental data and theoretical calculations (PET = positron emission tomography) Chem.-Eur. J. 2009, 15, 3736-3743
103. Tietze, L. F.; Schmuck, K. Sifa azide: a new building block for PET imaging using click chemistry Synlett 2011, 1697-1700
104. 18F-labeled peptides Eur. J. Inorg. Chem. 2011, 2238-2246
105. 18F radiopharmaceuticals Chem.-Eur. J. 2009, 15, 2140-2147
106. 18F-radiolabeling of peptides for PET imaging Angew. Chem., Int. Ed. 2008, 47, 4922-4925
107. 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks Bioconjugate Chem. 2008, 19, 1871-1879
108. 18F-labeling J. Fluorine Chem. 2011, 132, 27-34
109. 18F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride- acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET) Bioconjugate Chem. 2010, 21, 2289-2296
110. Graiver, D.; Farminer, K. W.; Narayan, R. A review of the fate and effects of silicones in the environment J. Polym. Environ. 2003, 11, 129-136
111. Fessenden, R. J.; Hartman, R. A. Metabolic fate of phenyltrimethylsilane and phenyldimethylsilane J. Med. Chem. 1970, 13, 52-54
112. Wakabayashi, K.; Sadakane, S.; Ando, M. Metabolism of simeconazole in rats J. Pestic. Sci. (Tokyo, Jpn.) 2005, 30, 90-98
113. Fang, J.; Gorrod, J. W.; Kajbaf, M.; Lamb, J. H.; Naylor, S. Investigation of the neuroleptic drug haloperidol and its metabolites using tandem mass spectrometry Int. J. Mass Spectrom. Ion Processes 1992, 122, 121-131